

Update on the voting outcomes of the 2017 AGM

Following the AstraZeneca PLC Annual General Meeting (“AGM”) held on 27 April 2017, the Remuneration Committee has reviewed the principal reasons for the low level of support received for resolution 6 (“To approve the Annual Report on Remuneration for the year ended 31 December 2016”).

Prior to the AGM, when developing the 2017 remuneration proposal, the Remuneration Committee undertook extensive consultation with the Company’s major shareholders and other key stakeholders. Our proposals, as detailed in the Annual Report on Remuneration for the year ended 31 December 2016, reflected elements of this feedback.

We are in contact with our major shareholders and the proxy voting advisors to understand their concerns in advance of our AGM to be held in 2018. The Remuneration Committee values the feedback and insights it gains through consultation and is committed to an ongoing dialogue with our shareholders.